Likewise, CTCs were enumerated in RAS-BRAF wild-type colorectal cancer patients receiving third-line anti-EGFR monoclonal antibodies, cetuximab or panitumumab and found that CTC status assessed early on during targeted therapy may predict treatment failure in advance compared to imaging-based tools [87]. The gene discussed is EGFR; the disease is colorectal cancer.